Barusiban
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C40H63N9O8S |
Molar mass | 830.049 g/mol |
3D model (JSmol) | |
| |
|
Barusiban (INN) (code name FE-200440) is a non-peptide drug which is among the most potent and selective oxytocin receptor antagonists known.[1][2] It was trialed by Ferring Pharmaceuticals as a treatment of preterm labor but failed to demonstrate effectiveness and was not pursued any further.[1][3]
See also
References
- 1 2 Rainer Landgraf; Inga D. Neumann (10 September 2008). Advances in Vasopressin and Oxytocin - From Genes to Behaviour to Disease. Elsevier. pp. 194,489. ISBN 978-0-08-093247-7.
- ↑ Stefan Offermanns; Walter Rosenthal (14 August 2008). Encyclopedia of Molecular Pharmacology. Springer Science & Business Media. pp. 1278–. ISBN 978-3-540-38916-3.
- ↑ Richard Ouellette; Joseph Joyce (25 October 2010). Pharmacology for Nurse Anesthesiology. Jones & Bartlett Publishers. pp. 450–. ISBN 978-0-7637-8607-6.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.